Tokyo, Jan. 30 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060483) titled 'Amivantamab and Lazertinib in EGFR-mutated NSCLC: Rick of Thromboembolism - Venous ThromboEmbolism' on Jan. 30.
Study Type:
Observational
Primary Sponsor:
Institute - Kyoto University Hospital
Condition:
Condition - Lung Cancer, Venous Thromboembolism (Pulmonary embolism and deep vein thrombosis)
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The primary objective of this study is to investigate the risk of venous thromboembolism (VTE) and bleeding associated with amivantamab/lazertinib combination therapy for EGFR-mutated NSCLC. Furthermore, we believe it wi...